Good
Mostly Aligned
Patient Risk:
Low
Summary
Most statements are general formulation/mechanism descriptions of dapagliflozin, which align with the provided label excerpts. However, several specificity claims about dosing/strengths and excipients are not supported by the provided FDA label excerpts (and some are generic/typical rather than label-backed), and the provided label excerpts concern FARXIGA (dapagliflozin) rather than the combination product named in the statements.
Category Scores
Accurate Statements
Dapagliflozin is an SGLT2 inhibitor.
Supported by the provided FARXIGA label section 12.1 Mechanism of Action: dapagliflozin is an inhibitor of SGLT2.
Unsupported Statements
Dapagliflozin–teneligliptin–metformin HCl combination tablets are formulated as a fixed-dose combination in one oral tablet.
The provided FDA-approved prescribing information excerpts are for FARXIGA (dapagliflozin) and do not include any information about teneligliptin/metformin combination products or fixed-dose combination formulation.
Each tablet contains dapagliflozin.
The excerpted FDA label is for FARXIGA (dapagliflozin) and does not support claims about a multi-ingredient combination tablet composition.
Each tablet contains teneligliptin.
Not supported by the provided FARXIGA label excerpts; FARXIGA contains dapagliflozin only.
Teneligliptin is a DPP-4 inhibitor.
Not supported by the provided FDA label excerpts (which do not discuss teneligliptin).
Each tablet contains metformin hydrochloride (HCl).
Not supported by the provided FARXIGA label excerpts.
Metformin hydrochloride is a biguanide.
Not supported by the provided FARXIGA label excerpts.
The tablets include inactive ingredients (excipients).
The provided excerpts include excipient-related language only in the contraindications section (hypersensitivity to excipients) but do not list excipients for this combination product; detailed excipient composition claims are not supported.
Inactive ingredients include tablet binders, fillers, disintegrants, lubricants, and coatings.
Not supported by the provided FDA label excerpts (no excipient list provided).
The exact concentrations (mg per tablet) of each active ingredient depend on the specific brand and strength sold in a given country.
Not supported by the provided FDA label excerpts.
Strength options (mg of each active ingredient per tablet) vary by manufacturer and marketed pack.
Not supported by the provided FDA label excerpts.
The precise excipient composition is product-specific.
Not supported by the provided FDA label excerpts.
Typical tablet excipients used in fixed-dose combinations may include binders.
Not supported by the provided FDA label excerpts.
Typical tablet excipients used in fixed-dose combinations may include fillers/diluents.
Not supported by the provided FDA label excerpts.
Typical tablet excipients used in fixed-dose combinations may include disintegrants.
Not supported by the provided FDA label excerpts.
Typical tablet excipients used in fixed-dose combinations may include lubricants/glidants.
Not supported by the provided FDA label excerpts.
Typical tablet excipients used in fixed-dose combinations may include coating agents.
Not supported by the provided FDA label excerpts.
The drug product is FARXIGA (dapagliflozin) with film-coated tablets (5 mg and 10 mg).
This is a label-aligned statement in the prompt context, but it does not support the combination-product composition claims earlier; moreover, the overall set of statements is internally about a different combination product (dapagliflozin–teneligliptin–metformin). The provided label excerpts do not address that combination product or its strengths.
Contradictions
Important Omissions
No attempt is made to align the combination-product ingredient composition (teneligliptin/metformin) with the FDA-approved prescribing information for FARXIGA; the provided label excerpts do not include these ingredients.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The only label-supported claim provided is that dapagliflozin is an SGLT2 inhibitor. The remaining claims are not supported by the provided FDA label excerpts (and several refer to a different combination product). Because the response does not provide dosing or safety instructions for the combination product, potential patient risk from the evaluated text is considered low, but the lack of label support for composition-related statements is a reliability concern.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims about a dapagliflozin–teneligliptin–metformin combination tablet’s contents and excipients are not supported by the provided FARXIGA prescribing information excerpts.
Suggested Improvement
Restrict claims to FDA-label-supported content for FARXIGA (dapagliflozin) or provide the correct FDA-approved prescribing information for the specific combination product; avoid unverifiable excipient composition and product-strength generalizations not present in the supplied label excerpts.